Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 63
Filter
1.
Breast Cancer Res Treat ; 178(3): 557-564, 2019 Dec.
Article in English | MEDLINE | ID: mdl-31512090

ABSTRACT

PURPOSE: In order to better define the breast cancer (BC) genetic risk factors in men, a germline investigation was carried out on 81 Male BC cases by screening the 24 genes involved in BC predisposition, genome stability maintenance and DNA repair mechanisms by next-generation sequencing. METHODS: Germline DNAs were tested in a custom multi-gene panel focused on all coding exons and exon-intron boundaries of 24 selected genes using two amplicon-based assays on PGM-Ion Torrent (ThermoFisher Scientific) and MiSeq (Illumina) platforms. All variants were recorded and classified by using a custom pipeline. RESULTS: Clinical pathological data and the family history of 81 Male BC cases were gathered and analysed, revealing the average age of onset to be 61.3 years old and that in 35 cases there was a family history of BC. Our genetic screening allowed us to identify a germline mutation in 22 patients (23%) in 4 genes: BRCA2, BRIP1, MUTYH and PMS2. Moreover, 12 variants of unknown clinical significance (VUS) in 9 genes (BARD1, BRCA1, BRIP1, CHEK2, ERCC1, NBN, PALB2, PMS1, RAD50) were predicted as potentially pathogenic by in silico analysis bringing the mutation detection rate up to 40%. CONCLUSION: As expected, a positive family history is a strong predictor of germline BRCA2 mutations in male BC. Understanding the potential pathogenicity of VUS represents an extremely urgent need for the management of BC risk in Male BC cases and their own families.


Subject(s)
Breast Neoplasms, Male/genetics , DNA Repair/genetics , Genetic Predisposition to Disease/genetics , Genetic Variation , High-Throughput Nucleotide Sequencing , Neoplasm Proteins/genetics , Adult , Aged , Aged, 80 and over , Breast Neoplasms, Male/blood , Breast Neoplasms, Male/pathology , Genetic Testing , Genome, Human/genetics , Germ-Line Mutation , Humans , Male , Middle Aged , Pedigree
2.
J Transl Med ; 17(1): 187, 2019 06 03.
Article in English | MEDLINE | ID: mdl-31159827

ABSTRACT

BACKGROUND: Tumors develop by progression through a series of stages. Every cell of the tumor microenvironment is constantly changing in the flow of the cancer progression. It has become clear in recent years that stroma is essential for tumor maintenance and growth. Here, we aimed to give a chronological order of gene expression changes given in the dynamical framework of microinvasive breast cancer microenvironment. METHODS: RNA-seq was performed on seven microinvasive breast cancers. For each of them we microdissected seven different portions of the tumor, four related to the breast epithelium and three to the stroma. Breast epithelium was chronologically subdivided in normal breast epithelium (NBE), carcinoma in situ (CIS), emerging invasive fingers (EIF) and invasive breast cancer (IBC). For each of the breast epithelium subdivisions we collected the adjacent stroma (S): S-NBE, S-EIF and S-IBC. RESULTS: The overall differentially expressed genes (DEGs) in all the compartments were analysed and evaluated to understand the pathways involved in tumor progression. Then we analysed the DEGs of the epithelial and stromal portions in comparison with the normal portions. We observed that the stromal cells are necessary for the development and the maintenance of the tumor, especially in tumor progression. Moreover the most important genes involved in the main metabolic pathways were analysed and the communications within the different cell compartments were highlighted. CONCLUSIONS: As a future perspective, a deeply study of the identified key genes, particularly in the stromal cells, will be crucial to develop an anticancer therapy that is undergoing a conversion from a cancer cell-centric strategy to a stroma-centric strategy, more genomically stable.


Subject(s)
Breast Neoplasms/genetics , Breast Neoplasms/pathology , Carcinoma, Intraductal, Noninfiltrating/genetics , Carcinoma, Intraductal, Noninfiltrating/pathology , Tumor Microenvironment/genetics , Breast/metabolism , Breast/pathology , Disease Progression , Female , Gene Expression Profiling , Gene Expression Regulation, Neoplastic , High-Throughput Nucleotide Sequencing , Humans , Metabolic Networks and Pathways/genetics , Neoplasm Invasiveness , Neoplasm Staging , Sequence Analysis, RNA , Stromal Cells/pathology
3.
J Geophys Res Atmos ; 123(2): 764-774, 2018 Jan 27.
Article in English | MEDLINE | ID: mdl-30505642

ABSTRACT

The probability density function (PDF) of the time intervals between subsequent extreme events in atmospheric Hg0 concentration data series from different latitudes has been investigated. The Hg0 dynamic possesses a long-term memory autocorrelation function. Above a fixed threshold Q in the data, the PDFs of the interoccurrence time of the Hg0 data are well described by a Tsallis q-Exponential function. This PDF behavior has been explained in the framework of superstatistics, where the competition between multiple mesoscopic processes affects the macroscopic dynamics. An extensive parameter µ, encompassing all possible fluctuations related to mesoscopic phenomena, has been identified. It follows a χ 2-distribution, indicative of the superstatistical nature of the overall process. Shuffling the data series destroys the long-term memory, the distributions become independent of Q, and the PDFs collapse on to the same exponential distribution. The possible central role of atmospheric turbulence on extreme events in the Hg0 data is highlighted.

4.
Breast Cancer Res Treat ; 170(3): 445-454, 2018 Aug.
Article in English | MEDLINE | ID: mdl-29616377

ABSTRACT

PURPOSE: Secretory breast cancer (SBC) is one of the rarest breast cancer (BC), representing the majority of BC in childhood. Nevertheless, it elicits a lot of interest both for the peculiar morphology and the characteristic genetic features. Currently, there is no consensus on optimal treatment strategy. Therefore, it is useful to report every case in order to establish treatment algorithms. METHODS: We describe the case of a 6-year-old boy diagnosed with a SBC, with peculiar genomic and immunohistochemical features. Moreover, we carried out a review of the literature in order to analyze the present state of knowledge about this rare entity. RESULTS: To the best of our knowledge, there are only 120 cases published in literature, only 32 in males and only 2 younger than 6 years. Furthermore, this one had peculiar genomic and immunohistochemical features. Indeed, even if SBC expresses basal-cell markers, our patient had a triple-negative tumor expressing both basal and luminal cell markers. Furthermore, the boy's genomic profile revealed not only positivity for the typical SBC's translocation t(12;15), but also for a 3q28 duplication, found in his father (healthy) and paternal grandfather (with a previous BC). None were positive for BRCA mutation. This locus includes only one gene encoding for a growth factor recently linked to Early Infantile Epileptic Encephalopathy-47 and Idiopathic ventricular tachycardia. Even if the literature does not provide evidence of a pathogenic role it is not possible to exclude a cancer-predisposing activity. CONCLUSIONS: SBC is a rare type of BC, characterized by triple-negative features with an unexpectedly good prognosis. More data are needed to fully understand the behavior of this cancer and genomic profiling could be helpful in improving its diagnosis and management.


Subject(s)
Biomarkers, Tumor , Breast Neoplasms, Male/diagnosis , Breast Neoplasms, Male/genetics , Breast Neoplasms/diagnosis , Breast Neoplasms/genetics , Carcinoma/diagnosis , Carcinoma/genetics , Gene Duplication , Biomarkers , Breast Neoplasms/metabolism , Breast Neoplasms, Male/metabolism , Carcinoma/metabolism , Child , Follow-Up Studies , Humans , Male , Tumor Burden , Ultrasonography
6.
Int J Cardiol ; 257: 243-246, 2018 04 15.
Article in English | MEDLINE | ID: mdl-28918896

ABSTRACT

BACKGROUND: Mobilization of endothelial progenitor cells (EPCs) into circulation from bone marrow in patients with acute myocardial infarction has strong scientific evidence; less is known about EPC mobilization in patients with stable coronary artery disease (CAD). The aim of this study was to investigate the association of stable ischemic heart disease with EPC levels in tissue and blood. METHODS: Fifty-five consecutive patients admitted to a single treatment center for valve or coronary artery bypass grafting (CABG) surgeries were included in the study. Blood samples were collected in the morning before surgery and analyzed by flow-cytometry to determine peripheral EPC levels (EPC/ml). Tissue EPC (CD34+VEGFR2+) levels were assessed on a right atrial appendage segment. RESULTS: Mean age was 76±5years, 48% were men, and 53% had CAD The number of CD34+ VEGFR2+ cells in the tissue of patients with CAD was significantly higher (p<0.005) and circulating EPC showed a tendency to be reduced by approximately 20% in peripheral blood of patients with CAD when compared to those without CAD. CONCLUSION: Patients with stable CAD had higher EPC density values (EPC/mm2) and were more likely to have lower EPC blood levels when compare with normal controls.


Subject(s)
Endothelial Progenitor Cells/physiology , Myocardial Ischemia/blood , Myocardial Ischemia/surgery , Aged , Aged, 80 and over , Cardiac Surgical Procedures/methods , Cardiac Surgical Procedures/trends , Coronary Artery Disease/blood , Coronary Artery Disease/diagnostic imaging , Coronary Artery Disease/surgery , Female , Flow Cytometry/methods , Flow Cytometry/trends , Humans , Male , Myocardial Ischemia/diagnostic imaging
7.
Andrologia ; 48(10): 1183-1187, 2016 Dec.
Article in English | MEDLINE | ID: mdl-27062069

ABSTRACT

The aim of this study was to evaluate the impact of group psychotherapy and the use of a phosphodiesterase-5 inhibitor (PDE-5i) in the early rehabilitation stage of patients with prostate cancer undergoing radical prostatectomy (RP). Fifty-six patients undergoing RP for prostate cancer were randomised into four groups, and 53 completed the protocol: Group 1 - control (n = 11), Group 2 - group psychotherapy (n = 16), Group 3 - lodenafil 80 mg/one tablet per week (n = 12) and Group 4 - group psychotherapy + lodenafil 80 mg/one tablet per week (n = 14). The groups were individually evaluated for erectile function (IIEF-5) and quality of life - QoL (SF-36) weekly, with two meetings held a week apart before the RP and 12 weekly meetings after surgery. The ages ranged from 39 to 76 years, average 61.84. There were no significant medication side effects. Only Group 4 showed improvement in intimacy with a partner and satisfaction with their sex life (P = 0.045 and P = 0.013 respectively), and with no significant worsening of the IIEF-5 (P = 0.250) reported. All groups showed worsening in the final result of the role limitations caused by physical problems (P = 0.009) and role limitations caused by emotional problems (P = 0.002) of the SF-36, but Group 4 had a significantly higher score for the role limitations caused by physical problems (P = 0.009) than the other groups. In conclusion, precocious integral treatment involving group psychotherapy and PDE-5i before and after RP led to less deterioration of erectile function and other domains related to physical aspects (SF-36), with improvement in intimacy with their partner and satisfaction in their sex life, being superior to single treatments.


Subject(s)
Carbonates/therapeutic use , Erectile Dysfunction/drug therapy , Penile Erection/drug effects , Phosphodiesterase 5 Inhibitors/therapeutic use , Piperazines/therapeutic use , Prostatectomy/adverse effects , Psychotherapy , Pyrimidines/therapeutic use , Quality of Life/psychology , Adult , Aged , Carbonates/pharmacology , Combined Modality Therapy , Erectile Dysfunction/etiology , Erectile Dysfunction/psychology , Humans , Male , Middle Aged , Penile Erection/psychology , Phosphodiesterase 5 Inhibitors/pharmacology , Piperazines/pharmacology , Prospective Studies , Prostatectomy/psychology , Prostatic Neoplasms/psychology , Prostatic Neoplasms/surgery , Pyrimidines/pharmacology , Treatment Outcome
8.
Eur J Histochem ; 60(1): 2563, 2016 Feb 01.
Article in English | MEDLINE | ID: mdl-26972711

ABSTRACT

The development of the human central nervous system represents a delicate moment of embryogenesis. The purpose of this study was to analyze the expression of multiple immunohistochemical markers in the stem/progenitor cells in the human cerebral cortex during the early phases of development.  To this end, samples from cerebral cortex were obtained from 4 human embryos of 11 weeks of gestation. Each sample was formalin-fixed, paraffin embedded and immunostained with several markers including GFAP, WT1, Nestin, Vimentin, CD117, S100B, Sox2, PAX2, PAX5, Tß4, Neurofilament, CD44, CD133, Synaptophysin and Cyclin D1. Our study shows the ability of the different immunohistochemical markers to evidence different zones of the developing human cerebral cortex, allowing the identification of the multiple stages of differentiation of neuronal and glial precursors. Three important markers of radial glial cells are evidenced in this early gestational age: Vimentin, Nestin and WT1. Sox2 was expressed by the stem/progenitor cells of the ventricular zone, whereas the postmitotic neurons of the cortical plate were immunostained by PAX2 and NSE. Future studies are needed to test other important stem/progenitor cells markers and to better analyze differences in the immunohistochemical expression of these markers during gestation.


Subject(s)
Antigens, Differentiation/biosynthesis , Cerebral Cortex/embryology , Embryo, Mammalian/embryology , Gene Expression Regulation, Developmental/physiology , Neural Stem Cells/metabolism , Cerebral Cortex/cytology , Embryo, Mammalian/cytology , Female , Humans , Immunohistochemistry , Male , Neural Stem Cells/cytology
9.
J Neurooncol ; 126(2): 265-70, 2016 Jan.
Article in English | MEDLINE | ID: mdl-26511493

ABSTRACT

Glioblastoma is the most common and aggressive malignant primary brain tumor. Despite decades of research and the advent of new therapies, patients with glioblastoma continue to have a very poor prognosis. Radiation therapy has a major role as adjuvant treatment for glioblastoma following surgical resection. Many studies have shown that polymorphisms of genes involved in pathways of DNA repair may affect the sensitivity of the cells to treatment. Although the role of these polymorphisms has been investigated in relation to response to radiotherapy, their role as predisposing factors to glioblastoma has not been clarified yet. In the present study, we evaluated the association between polymorphisms in DNA repair genes, namely: XRCC1 rs25487, XRCC3 rs861539 and RAD51 rs1801320, with the susceptibility to develop glioblastoma. Eighty-five glioblastoma patients and 70 matched controls were recruited for this study. Data from the 1000 Genomes Project (98 Tuscans) were also downloaded and used for the association analysis. Subjects carrying RAD51 rs1801320 GC genotype showed an increased risk of glioblastoma (GC vs GG, χ(2) = 10.75; OR 3.0087; p = 0.0010). The C allele was also significantly associated to glioblastoma (χ(2) = 8.66; OR 2.5674; p = 0.0032). Moreover, RAD51 rs1801320 C allele increased the risk to develop glioblastoma also when combined to XRCC1 rs25487 G allele and XRCC3 rs861539 C allele (χ(2) = 6.558; p = 0.0053).


Subject(s)
Brain Neoplasms/genetics , DNA Repair , Glioblastoma/genetics , Polymorphism, Single Nucleotide , Rad51 Recombinase/genetics , Aged , DNA-Binding Proteins/genetics , Female , Gene Frequency , Genetic Association Studies , Genetic Predisposition to Disease , Humans , Male , Middle Aged , Risk Factors , X-ray Repair Cross Complementing Protein 1
11.
Actas Urol Esp ; 38(6): 385-90, 2014.
Article in English, Spanish | MEDLINE | ID: mdl-24360771

ABSTRACT

OBJECTIVES: To measure the impact of psychotherapy associated to the use of Tadalafil in the improvement of erectile function after radical prostatectomy. METHODS: From 132 patients surgically treated for prostate cancer, thirty sequential patients with bilateral nerve sparing, low risk controlled disease and post-surgery erectile dysfunction (ED) took Tadalafil 20mg and underwent psychotherapy sessions, both weekly for three months. Patients were interviewed to establish the quality of erection using the instrument IIEF-5 and to measure psychological features impacting erectile function, aspects related to function, dysfunction, physical and emotional discomfort were evaluated with the help of an intensity scale. RESULTS: The average age was 62.5 (46 to 77 years), 96.7% had a stable relationship, 56.6% of the patients accepted the diagnosis and 43.2% exhibited defense mechanisms (3.3% negation, 6.6% revulsion, 33.3% concern). A positive correlation was observed between erectile function and time exposed to treatment (IIEF-5 - 9.7 to 13.3, p=0.0006), with increased satisfaction with life in general (2.1 to 2.7, P=.028) and sexual life (3.1 to 3.7, P=.028), added to facilitation of expressing feelings/emotions (1.8 to 3.0, P=.0008). Satisfaction with relationship and intimacy with partner did not present significant improve (P=.12 and P=.61, respectively). CONCLUSIONS: A holistic patient care with more complete ED rehabilitation includes psychotherapy with a positive correlation between erectile function and treatment exposition. Psychotherapy allowed the identification of important spouse related factors in this scenario.


Subject(s)
Erectile Dysfunction/rehabilitation , Phosphodiesterase 5 Inhibitors/therapeutic use , Prostatectomy , Psychotherapy , Tadalafil/therapeutic use , Aged , Combined Modality Therapy , Erectile Dysfunction/etiology , Humans , Male , Middle Aged , Prospective Studies , Prostatectomy/adverse effects
13.
Endocr Relat Cancer ; 17(1): 1-6, 2010 Mar.
Article in English | MEDLINE | ID: mdl-19755524

ABSTRACT

Aberrant accumulation of beta-catenin has been found in various types of human tumors. The aim of this study was to evaluate whether Wnt/beta-catenin signaling is activated in parathyroid carcinomas and adenomas. We studied 154 parathyroid tumors (18 carcinomas (13 with distant metastases), six atypical adenomas, and 130 adenomas). Three normal parathyroid tissues were used as control. Direct sequencing of exon 3 of the CTNNB1 gene showed absence of stabilizing mutations in all the tumors. Immunostaining of beta-catenin was performed in all carcinomas and in 66 adenomas (including three atypical). Normal parathyroid showed a homogeneous distinct outer cell membrane staining in the majority of cells and no nuclear staining. A weak cytoplasmic staining was observed in one case. All tumors showed negative nuclear staining. With the exception of one carcinoma, which had a negative membrane staining, all other samples showed a membrane staining which was similar to that of the normal parathyroid. beta-Catenin expression was heterogeneous with a range of positive cells between 5 and 80%, independently of tumor type. Our results suggest that the Wnt/beta-catenin signaling pathway is not involved in the development of parathyroid carcinomas and adenomas.


Subject(s)
Adenoma/physiopathology , Carcinoma/physiopathology , Neoplasm Proteins/physiology , Parathyroid Neoplasms/physiopathology , Signal Transduction/physiology , Wnt Proteins/physiology , beta Catenin/physiology , Adenoma/chemistry , Adenoma/genetics , Carcinoma/chemistry , Carcinoma/genetics , Cell Transformation, Neoplastic/genetics , Cytoplasm/chemistry , DNA Mutational Analysis , Exons/genetics , Humans , Membrane Proteins/analysis , Neoplasm Proteins/analysis , Parathyroid Neoplasms/chemistry , Parathyroid Neoplasms/genetics , beta Catenin/analysis
14.
Actas Urol Esp ; 32(4): 411-6, 2008 Apr.
Article in Spanish | MEDLINE | ID: mdl-18540262

ABSTRACT

OBJECTIVE: Analyze the treatment satisfaction and impact on patients with localized prostate cancer. METHODS: One-hundred and eighty patients, with mean age of 60 years, were divided into three groups: group I--100 patients submitted to radical retropubic prostatectomy (RRP), group II--40 patients who underwent radiotherapy (RT), and group III--40 healthy men. A questionnaire was applied to the groups to assess physical and psychological changes 18 months after treatment. The investigational tool was based on two questionnaires; first: SF-36 (Short Form Health Survey), second: FACT-P (Functional Assessment Cancer Therapy). RESULTS: In group I, 70% never used pads, 5% presented with complete urinary incontinence, and 10% reported occasional stool leakage. In group II, 85% did not use pads and 5% reported two pads a day; 15% reported stool leakage or intestinal cramps. Sexual dysfunction was similar in both groups: 75% of the surgical group and 72.5% of the radiotherapy group reported erectile dysfunction. In the control group, 40% reported erectile dysfunction; 10% reported occasional stool leakage and none had changes regarding the overall treatment-related satisfaction. Seventy-eight percent of the RRP group and 77.5% of the RT group reported being happy respecting satisfaction with the accepted or chosen treatment, and affirmed that would choose it again. CONCLUSIONS: The assessment of treatment-related satisfaction determines the treatment tolerability. This study's results did not show any significant changes in this issue between both treatment modalities (p>0.05).


Subject(s)
Patient Satisfaction , Prostatectomy , Prostatic Neoplasms/radiotherapy , Prostatic Neoplasms/surgery , Adult , Aged , Humans , Male , Middle Aged , Prostatic Neoplasms/psychology , Surveys and Questionnaires
15.
Br J Cancer ; 98(10): 1619-29, 2008 May 20.
Article in English | MEDLINE | ID: mdl-18443598

ABSTRACT

Metronomic chemotherapy refers to the administration of chemotherapy at low, nontoxic doses on a frequent schedule with no prolonged breaks. The aim of the study is to rationally develop a CPT-11 metronomic regimen in preclinical settings of colon cancer. In vitro cell proliferation, apoptosis and thrombospondin-1/vascular endothelial growth factor (TSP-1/VEGF) expression analyses were performed on endothelial (HUVEC, HMVEC-d) and colorectal cancer (HT-29, SW620) cells exposed for 144 h to metronomic concentrations of SN-38, the active metabolite of CPT-11. HT-29 human colorectal cancer xenograft model was used, and tumour growth, microvessel density and VEGF/TSP-1 quantification was performed in tumours. In vitro and in vivo combination studies with the tyrosine inhibitor semaxinib were also performed. SN-38 preferentially inhibited endothelial cell proliferation alone and interacted synergistically with semaxinib; it induced apoptosis and increased the expression and secretion of TSP-1. Metronomic CPT-11 alone and combined with semaxinib significantly inhibits tumour growth in the absence of toxicity, which was accompanied by decreases in microvessel density and increases in TSP-1 gene expression in tumour tissues. In vitro results show the antiangiogenic properties of low-concentration SN-38, suggesting a key role of TSP-1 in this effect. In vivo, the CPT-11 metronomic schedule is effective against tumour and microvessel growth without toxic effect on mice.


Subject(s)
Angiogenesis Inhibitors/pharmacology , Antineoplastic Agents, Phytogenic/pharmacology , Antineoplastic Combined Chemotherapy Protocols/pharmacology , Camptothecin/analogs & derivatives , Colorectal Neoplasms/blood supply , Colorectal Neoplasms/drug therapy , Indoles/pharmacology , Pyrroles/pharmacology , Angiogenesis Inhibitors/administration & dosage , Animals , Antineoplastic Agents, Phytogenic/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Apoptosis/drug effects , Camptothecin/administration & dosage , Camptothecin/pharmacology , Cell Proliferation/drug effects , Enzyme-Linked Immunosorbent Assay , Gene Expression Regulation, Neoplastic/drug effects , HT29 Cells , Humans , Immunoenzyme Techniques , Immunohistochemistry , Indoles/administration & dosage , Irinotecan , Male , Mice , Mice, Nude , Microcirculation/drug effects , Pyrroles/administration & dosage , Thrombospondin 1/drug effects , Thrombospondin 1/metabolism , Transplantation, Heterologous , Vascular Endothelial Growth Factor A/drug effects , Vascular Endothelial Growth Factor A/metabolism
16.
Radiol Med ; 112(2): 272-86, 2007 Mar.
Article in English, Italian | MEDLINE | ID: mdl-17361370

ABSTRACT

PURPOSE: The aim of this study was to evaluate the role of magnetic resonance imaging (MRI) in patients with microcalcifications classed as Breast Imaging Reporting and Data Systems (BI-RADS) 3-5. MATERIALS AND METHODS: Fifty-five patients with mammographic microcalcifications classified as BI-RADS categories 3, 4 or 5 underwent MRI and biopsy with stereotactic vacuum-assisted biopsy (VAB). Our gold standard was microhistology in all cases and histology with histological grading in patients who underwent surgery. Patients with a microhistological diagnosis of benign lesions underwent mammographic follow-up for at least 12 months. MRI was performed with a 1.5-Tesla (T) unit, and T1 coronal three-dimensional (3D) fast low-angle shot sequences were acquired before and after injection of paramagnetic contrast agent (0.1 mmol/kg). MRI findings, according to the Fisher score, were classified into BI-RADS classes. In patients with cancer who underwent surgery, we retrospectively compared the extension of the mammographic and MRI findings with histological extension. RESULTS: Histology revealed 26 ductal in situ cancers (DCIS) and ductal microinvasive cancers (DCmic), three atypical ductal hyperplasias (ADH) and 26 benign conditions. Histological grading of the 26 patients with cancer revealed four cases of G1, 11 cases of G2 and 11 cases of G3. If we consider mammographic BI-RADS category 3 as benign and BI-RADS 4 and 5 as malignant, mammography had 77% sensitivity, 59% specificity, 63% positive predictive value (PPV), 74% negative predictive value (NPV) and 67.2% diagnostic accuracy. If we consider MRI BI-RADS categories 1, 2 and 3 as benign and 4 and 5 as malignant, MRI had 73% sensitivity, 76% specificity, 73% PPV, 76% NPV and 74.5% diagnostic accuracy. As regards disease extension, mammography had 45% sensitivity and MRI had 84.6% sensitivity. CONCLUSION: Mammography and stereotactic biopsy still remain the only techniques for characterising microcalcifications. MRI cannot be considered a diagnostic tool for evaluating microcalcifications. It is, however, useful for identifying DCIS with more aggressive histological grades. An important application of MRI in patients with DCIS associated with suspicious microcalcifications could be to evaluate disease extension after a microhistological diagnosis of malignancy, as it allows a more accurate presurgical planning.


Subject(s)
Breast Neoplasms/diagnosis , Breast/pathology , Calcinosis/diagnosis , Carcinoma, Ductal, Breast/diagnosis , Carcinoma, Intraductal, Noninfiltrating/diagnosis , Magnetic Resonance Imaging , Mammography , Adult , Aged , Biopsy , Breast Neoplasms/diagnostic imaging , Contrast Media , Female , Humans , Hyperplasia/diagnosis , Magnetic Resonance Imaging/methods , Middle Aged , Sensitivity and Specificity
17.
Clin Endocrinol (Oxf) ; 65(4): 544-8, 2006 Oct.
Article in English | MEDLINE | ID: mdl-16984250

ABSTRACT

BACKGROUND: Iodide (I(-)) is crucial for foetal thyroid function. Foetal iodide results from maternal circulating iodide and from deiodination of iodothyronines within the placenta. The Na(+)/I(-) symporter (NIS) localized in placental cells appears to be involved in iodide exchange. Low NIS expression has been reported in trophoblast cells from the first trimester and pregnancy at term. AIMS: The aim of this study was to examine NIS expression by immunohistochemistry in the major components of human ovular tissue and placenta. MATERIALS AND METHODS: Formalin-fixed and paraffin-embedded specimens of placental tissue from the first trimester and at term were analysed. NIS expression was quantified as percentage of NIS-positive cells/total cells. NIS expression was also evaluated by real-time polymerase chain reaction (RT-PCR) in five first-trimester and five at-term placental specimens. RESULTS: In the first-trimester specimens heterogeneous NIS immunoreactivity was found in cyto-syncytiotrophoblast cells, with a range of NIS-positive cells from 5% to 80% (mean +/- SD 21.85 +/- 23.95), in mesenchymal and endothelial cells from 1% to 40% (14.5 +/- 11.16), in decidual cells from 5% to 40% (10.38 +/- 11.98) and in endometrial glands from 3% to 40% (21.86 +/- 13.93). In specimens from placenta at term, NIS-positive cyto-syncytiotrophoblast cells were between 5% and 40% (mean 17.85 +/- 18.15), mesenchymal and endothelial cells between 1% and 40% (13.67 +/- 12.16), decidual tissue between 5% and 30% (16.43 +/- 9.08), and endometrial glands between 3% and 40% (16.67 +/- 15.27). No significant differences in NIS expression were observed between the first trimester and placenta at term. A similar level of mRNA expression for the NIS gene was obtained by RT-PCR both in ovular material of the first trimester and in placenta at term. CONCLUSIONS: We found NIS to be expressed in various placental and ovular components and its expression to remain constant during pregnancy.


Subject(s)
Placenta/chemistry , Symporters/analysis , Decidua/chemistry , Endometrium/chemistry , Endothelial Cells/chemistry , Female , Gene Expression , Gestational Age , Humans , Immunohistochemistry/methods , Mesoderm/chemistry , Pregnancy , RNA, Messenger/analysis , Reverse Transcriptase Polymerase Chain Reaction , Symporters/genetics , Thyroid Gland/chemistry , Trophoblasts/chemistry
18.
Br J Cancer ; 95(2): 204-9, 2006 Jul 17.
Article in English | MEDLINE | ID: mdl-16804521

ABSTRACT

Thyroid fine-needle aspiration biopsy (FNA)-cytology is widely used for the preoperative characterisation of thyroid nodules but this task is difficult for follicular lesions, which often remain undefined. We propose a strategy for improving the preoperative characterisation of selected follicular thyroid proliferations, which is based on large needle aspiration biopsy (LNAB) and galectin-3 expression analysis. Eighty-five thyroid specimens were obtained by LNAB (20-gauge needles) from thyroid nodules with indeterminate follicular FNA-cytology. Aspirated material was processed as a tissue microbiopsy to obtain cell blocks for both cyto/histo-morphological evaluation and galectin-3 expression analysis, by using a purified monoclonal antibody to galectin-3 and a biotin-free immunoperoxidase staining method. Preoperative diagnosis was compared to the final histology. LNAB and cell-block technique allow a preliminary distinction between nodules with a homogeneous microfollicular/trabecular structure, as frequently observed in tumours, and lesions with mixed normo-micro-macrofollicular architecture, as observed in goitre. Furthermore, LNAB provides optimal substrates for galectin-3 expression analysis. Among 85 cases tested, 14 galectin-3-positive cases were discovered preoperatively (11 thyroid cancers and three adenomas confirmed at the final histology), whereas galectin-3-negative cases were 71 (one carcinoma and 70 benign proliferations at the final histology). Sensitivity, specificity and diagnostic accuracy of this integrated morphologic and phenotypic diagnostic approach were 91.6, 97.2 and 95.3%, respectively. In conclusion, LNAB plus galectin-3 expression analysis when applied preoperatively to selected thyroid nodules candidate to surgery can potentially reduce unnecessary thyroid resections.


Subject(s)
Biopsy, Needle/methods , Galectin 3/analysis , Goiter/diagnosis , Thyroid Neoplasms/diagnosis , Thyroid Nodule/diagnosis , Adult , Biopsy, Needle/instrumentation , Female , Goiter/pathology , Goiter/surgery , Humans , Male , Sensitivity and Specificity , Thyroid Neoplasms/pathology , Thyroid Neoplasms/surgery , Thyroid Nodule/pathology , Thyroid Nodule/surgery
19.
J Pathol ; 209(4): 436-44, 2006 Aug.
Article in English | MEDLINE | ID: mdl-16710841

ABSTRACT

The hypothesis that a retrovirus homologous to the mouse mammary tumour virus (MMTV) is involved in human breast cancer aetiology has fascinated scientists from many years, but it has never been convincingly demonstrated. Renewed interest in this hypothesis developed when an MMTV env gene-like sequence was found in 38% of human breast cancer tissues. Whereas some subsequent studies confirmed these findings, others did not. The main reasons for this discrepancy, among others, are the different sensitivities and technical details of current molecular approaches to the detection of these sequences. This study is an attempt to find sensitive and reproducible conditions capable of detecting MMTV env-like sequence in human samples. To this end, we first developed a fluorescence nested-PCR (FN-PCR) method that was able to detect very low copies of the viral genome, and then screened a panel of 45 frozen breast cancer samples obtained by laser microdissection. The MMTV env gene-like sequence was found in 15 (33%) of the human breast cancers analysed, whereas the same sequence was detectable neither in normal tissues nor in other types of tumour. Sequence analysis revealed 96% homology with the MMTV genome, but no other significant similarities with the human genome. The combined use of frozen material, microdissected cell populations and FN-PCR provides a novel, sensitive, robust, non-radioactive and fast methodology for the molecular detection of human-MTV. This approach might be successfully used in large molecular studies that aim to investigate the hypothesis of a retroviral aetiology of human breast cancer.


Subject(s)
Breast Neoplasms/virology , Genes, env , Mammary Tumor Virus, Mouse/genetics , Retroviridae Infections/complications , Base Sequence , Cloning, Molecular , DNA, Neoplasm/analysis , DNA, Viral/analysis , Female , Humans , Lasers , Microdissection/methods , Molecular Sequence Data , Polymerase Chain Reaction/methods , Sequence Alignment , Sequence Homology
20.
Br J Cancer ; 93(4): 406-11, 2005 Aug 22.
Article in English | MEDLINE | ID: mdl-16052214

ABSTRACT

This trial was conducted to assess the activity and tolerability of the gemcitabine, epirubicin, taxol triplet combination in patients with operable breast cancer. After core biopsy, 43 women with stage II-IIIA breast cancer were treated with gemcitabine 1000 mg m(-2) over 30 min on days 1 and 4, epirubicin 90 mg m(-2) as an intravenous bolus on day 1, and taxol 175 mg m(-2) as a 3-h infusion on day 1, every 21 days for four cycles. The primary end point was the percentage of pathological complete responses (pCR) in the breast; secondary end points were tolerability, clinical response rates, overall and progression-free survival, tumour biomarkers before and after primary chemotherapy (PCT). All patients were included in safety and survival analyses; 41 eligible patients were evaluated for response. The overall clinical response rate was 87.8% (95% CI 77.8-97.8), with 26.8% complete responses (95% CI 13.3-40.3). A pCR in the breast was observed in six patients (14.6%; 95% CI 3.8-25.4); 15 patients (36.6%; 95% CI 21.9-51.3) had negative axillary lymph nodes. Grade 4 neutropenia was observed in 67.4% of the patients; febrile neutropenia occurred in 1.9% of cycles (granulocyte colony-stimulating factor was used in 3.2% of the cycles to shorten the duration of neutropenia). A statistically significant difference between Mib-1 at baseline (> or =20% in 71.4% of the patients) and at definitive surgery (28.6%, P < 0.05) was observed. The gemcitabine, epirubicin, taxol regimen is active and well tolerated as PCT for operable breast cancer. This combination allows the administration of full doses of active agents with a low incidence of febrile neutropenia.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Breast Neoplasms/drug therapy , Adult , Aged , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Biomarkers, Tumor , Breast Neoplasms/surgery , Combined Modality Therapy , Deoxycytidine/administration & dosage , Deoxycytidine/analogs & derivatives , Epirubicin/administration & dosage , Female , Humans , Infusions, Intravenous , Injections, Intravenous , Middle Aged , Survival Analysis , Taxoids/administration & dosage , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...